Vaccinations
6 cases on vaccine decisions in immunocompromised and comorbid patients, post-marketing safety signal interpretation, product-choice sequencing, and vaccine timing around immunosuppressive therapy — choose a case below to open its full multi-voice debate.
A kidney transplant recipient needs to travel for work into a yellow fever–endemic region. The vaccine she cannot safely receive and the disease she cannot safely encounter are both real — the disagreement is over what to do with a live-vaccine contraindication that has no expiration date.
An older man with COPD and a remote, infection-triggered episode of Guillain-Barré syndrome is offered RSV vaccination. A new, small post-marketing safety signal for the vaccine sits uneasily against a history that most guidance says shouldn’t count against him — but nobody is fully certain why the signal exists yet.
A patient vaccinated under an outdated pneumococcal schedule needs her regimen brought current. The sequencing question has a clear answer; the product choice underneath it, current guideline in hand, genuinely does not.
A patient with active, erosive rheumatoid arthritis needs a JAK inhibitor that carries a well-documented shingles risk, and hasn’t yet completed his zoster vaccine series. Neither drug is optional — the disagreement is over how many weeks of delay the disease itself can actually afford.
A college athlete with a documented, fully-recovered episode of mRNA vaccine–associated myocarditis now faces an institutional vaccination requirement. Real recurrence uncertainty sits against a real, separate infection risk — and the first question may not be biological at all.
A 38-year-old never vaccinated against HPV asks for it now, newly single after a long marriage. ACIP’s own shared clinical decision-making category exists for exactly this situation — which means the guideline hands the real judgment call to the room, not away from it.